Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.

ABSTRACT: Adoptive cell therapy with ex vivo expanded tumor infiltrating lymphocytes or gene engineering T cells expressing chimeric antigen receptors (CAR) is a promising treatment for cancer patients. This production utilizes T-cell activation and transduction with activation beads and RetroNectin, respectively. However, the high cost of production is an obstacle for the broad clinical application of novel immunotherapeutic cell products. To facilitate production we refined our approach by using artificial antigen presenting cells (aAPCs) with receptors that ligate CD3, CD28, and the CD137 ligand (CD137L or 41BBL), as well as express the heparin binding domain (HBD), which binds virus for gene-transfer. We have used these aAPC for ex vivo gene engineering and expansion of tumor infiltrating lympho

SUBMITTER: Shrestha B 

PROVIDER: S-EPMC7077957 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature